Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma
Extended follow-up of four patients with multiple myeloma treated with in vivo BCMA CAR-T cells showed limited duration of response in three patients, while one patient had sustained response to 15 months.